Combined p53 and Bcl2 Immunophenotypes in Prognosis of Vietnamese Invasive Breast Carcinoma: A Single Institutional Retrospective Analysis

• Published in: Technology in cancer research & treatment Vol. 19; p. 1533033820983081
• Main Authors: Van Nguyen, Chu, Nguyen, Quang Tien, Vu, Ha Thi Ngoc, Phung, Huyen Thi, Pham, Khoa Hong, Le, Roanh Dinh
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01-01-2020; Sage Publications Ltd; SAGE Publishing
• Subjects: Breast cancer; Breast carcinoma; Chemotherapy; Clinical outcomes; Invasiveness; Medical prognosis; Multivariate analysis; Original; p53 Protein; Patients; Proteins; Survival; breast cancer; immunohistochemistry; p53 and Bcl2 immunophenotype; prognosis
• ISSN: 1533-0346; 1533-0338
• DOI: 10.1177/1533033820983081

Background:
Aberrant of p53 and Bcl2 genes cause changes in the quantity and quality of their proteins and contribute to the pathogenesis of some cancer types including breast cancer. Expression of p53 and Bcl2 were associated to adverse clinical outcomes in breast cancer.
Purpose:
To predict the survival outcomes of invasive breast cancer in Vietnam, using immunohistochemical expression of p53, Bcl2 proteins.
Methods:
The current study was conducted on 526 breast cancer patients who had surgical operations, but had not received neo-adjuvant chemotherapy, from 2011 to 2014. The clinicopathological characteristics were recorded. Immunohistochemical staining was performed on p53, Bcl2 markers. Expression of p53 and Bcl2 were paired into different immunophenotypes for analysis with clinicopathological characteristics and survival. All breast cancer patients’ survival were analyzed by using Kaplan-Meier and Log-Rank models.
Results:
The presence of p53 protein was detected in 44.1%. Positive p53, and p53+Bcl2- immunophenotype were significantly associated with poorer prognostic features. In contrast, the positive Bcl2 protein accounted on 57.6%, and combination of p53-Bcl2+ were strong correlated with better clinicopathological parameters. Bcl2 positivity was observed in higher than the negative Bcl2 in the five-year OS (Overall survival) proportion (91.2 vs 79.4%, respectively) (p < 0.05). Multivariate analysis revealed that the expression of p53, Bcl2 or combinations of these 2 proteins was no longer remained as an independent prognostic variable.
Conclusion:
The Bcl2 positivity had a distinct OS and DFS (Disease free survival). The expression of p53 and Bcl2 are inversely correlated to clinical outcomes in breast cancer.